Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia

INTRODUCTION: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder and regarded as one of the most frequent genetic causes of infant mortality. The aim of this study is to develop a cost-effectiveness analysis of AVXS-101 (Onasemnogene Abeparvovec/Zolgensma(®)) and nusinersen (Spinra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tianjiao, Scuffham, Paul, Byrnes, Joshua, Downes, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618547/
https://www.ncbi.nlm.nih.gov/pubmed/35980467
http://dx.doi.org/10.1007/s00415-022-11319-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618547/
https://www.ncbi.nlm.nih.gov/pubmed/35980467
http://dx.doi.org/10.1007/s00415-022-11319-0

Ejemplares similares